Retrospective Study of Medication Adherence Among Adults with Metastatic Colorectal Cancer

Analysis Group client Taiho Oncology, Inc. announced real-world medication adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF® (trifluridine and tipiracil) or Stivarga® (regorafenib). The third most common type of cancer in the United States, excluding skin cancer, mCRC is also a leading cause of cancer-related deaths among both men and women. 

Using data from the IQVIA™ Real-World Data Adjudicated Claims-US database, the retrospective study found that treatment with LONSURF® was associated with significantly higher medication adherence and longer time to discontinuation compared to treatment with regorafenib. The study was conducted by an Analysis Group team – including Managing Principal Mei Sheng Duh and Vice Presidents François Laliberté and Mihran Yenikomshian – in collaboration with Anuj Patel, MD, of Dana-Farber Cancer Institute. The study data was presented by Dr. Patel at the 2018 ASCO Quality of Care Symposium (ASCO QCS) on September 28, 2018.

Read Taiho Oncology's Press Release

View the ASCO QCS Poster